SEC Tracker
Get the app

BridgeBio Pharma BBIO

BridgeBio Pharma gets FDA NDA acceptance for infigratinib

Form
8-K
Filed
Importance
Routine
  1. FDA accepted NDA for infigratinib with Priority Review
  2. PDUFA target action date is February 4, 2027
  3. PROPEL 3 trial showed significant efficacy in achondroplasia
  4. Oral infigratinib could be first approved oral therapy for children with achondroplasia

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  3. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  4. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  5. Repligen RGEN public float $6.0B, Jun 30, 2025